Bayer To Present Data On Development Compound BAY 73-4506 At 45th Annual Meeting Of The American Society Of Clinical Oncology

Main Category: Cancer / Oncology
Also Included In: Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 23 May 2009 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Bayer HealthCare Pharmaceuticals, Inc. announced that new data on Bayer's novel anti-cancer development candidate BAY 73-4506 (DAST-Inhibitor) will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 - June 2.

"Bayer is committed to expanding our oncology franchise, and the oral multi-kinase inhibitor BAY 73-4506 is one of the promising compounds in the company's pipeline," said Kemal Malik, MD, member of the Board of Management and Chief Medical Officer and Head of Global Development at Bayer HealthCare. "We look forward to determining the role of BAY 73-4506, along with other compounds in our franchise, in creating potential treatment options for patients afflicted with various cancers."

The BAY 73-4506 data being presented are:

BAY 73-4506

-- Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma

-- Dirk Strumberg, MD, Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Germany

-- Abstract 3560, Poster, Saturday, May 30, 2009, 8:00-11:00 a.m., Level 2, West Hall C

-- Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer

-- Professor Tim Eisen, PhD, Addenbrooke's Hospital and the University of Cambridge, UK

-- Abstract 5033, Poster Discussion, Friday, May 29, 2009, 2:00-6:00 p.m., Level 2, W230A

About BAY 73-4506 (DAST-Inhibitor)

BAY 73-4506 is a novel oral multi-kinase inhibitor with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). BAY 73-4506 has been shown to inhibit tumor growth in preclinical models by hitting targets along a spectrum of angiogenic pathways, including VEGFR and TIE2. BAY 73-4506 has also been shown to prevent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The mechanism may offer promise to treat a broad spectrum of tumors.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a subsidiary of Bayer Corporation. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. The company's aim is to provide products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

Source: Bayer HealthCare Pharmaceuticals Inc